Published in Int J Radiat Oncol Biol Phys on January 15, 1994
Timing of radiotherapy in small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 0.75
Comments on "Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer". Int J Radiat Oncol Biol Phys (1995) 0.75
Lambda replacement vectors carrying polylinker sequences. J Mol Biol (1983) 32.76
Differentiation of receptor systems activated by sympathomimetic amines. Nature (1967) 11.46
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature (1991) 7.98
Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke (1996) 7.81
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem (1995) 6.25
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet (1993) 6.08
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet (2001) 3.45
High-performance lithium-ion anodes using a hierarchical bottom-up approach. Nat Mater (2010) 3.25
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol (1988) 2.91
Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A (1994) 2.87
Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys (1994) 2.77
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol (2006) 2.66
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab (2000) 2.52
CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology (2011) 2.41
Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet (1981) 2.36
Cancer care workers in Ontario: prevalence of burnout, job stress and job satisfaction. CMAJ (2000) 2.32
Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol (1996) 2.31
Do minutes count? Consultation lengths in general practice. J Health Serv Res Policy (1998) 2.23
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1993) 2.22
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control (1997) 2.08
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1991) 2.06
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A (1991) 2.04
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med (1994) 1.97
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Does a centralized radiotherapy system provide adequate access to care? J Clin Oncol (1997) 1.90
Cyclin D and oncogenesis. Curr Opin Genet Dev (1993) 1.88
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol (1990) 1.88
The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev (1999) 1.78
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol (1992) 1.77
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer (2004) 1.76
CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol (1996) 1.72
Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol (1992) 1.72
PRAD1/cyclin D1 proto-oncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer (1993) 1.70
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem (1992) 1.66
Ethical issues arising from human genetics. J Med Ethics (1976) 1.65
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol (2007) 1.63
Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer (2000) 1.61
Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck (2001) 1.61
Left ventricular mass in the elderly. The Cardiovascular Health Study. Hypertension (1997) 1.59
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast. Cancer (1996) 1.57
High frequency hearing loss correlated with mutations in the GJB2 gene. Hum Genet (2000) 1.54
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2010) 1.53
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol (1984) 1.51
The Riyadh Intensive Care Program applied to a mortality analysis of a teaching hospital intensive care unit. Anaesthesia (1992) 1.50
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care (2007) 1.49
A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol (1993) 1.48
Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene (1991) 1.44
Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore) (2001) 1.43
Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer (1999) 1.43
Intensity-modulated radiotherapy in the treatment of breast cancer. Clin Oncol (R Coll Radiol) (2012) 1.42
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol (1989) 1.42
Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns (2001) 1.42
Cyclins and oncogenesis. Biochim Biophys Acta (1993) 1.41
Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res (1998) 1.40
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med (1988) 1.39
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol (2004) 1.39
Extent and variation of omeprazole prescribing in an elderly population of Ontario. Ann Pharmacother (1997) 1.38
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med (1987) 1.38